LLY

743.42

+1.14%↑

JNJ

178.62

+0.73%↑

ABBV

212.4

+0.07%↑

UNH

310.19

+1.43%↑

NVO

56.31

-0.48%↓

LLY

743.42

+1.14%↑

JNJ

178.62

+0.73%↑

ABBV

212.4

+0.07%↑

UNH

310.19

+1.43%↑

NVO

56.31

-0.48%↓

LLY

743.42

+1.14%↑

JNJ

178.62

+0.73%↑

ABBV

212.4

+0.07%↑

UNH

310.19

+1.43%↑

NVO

56.31

-0.48%↓

LLY

743.42

+1.14%↑

JNJ

178.62

+0.73%↑

ABBV

212.4

+0.07%↑

UNH

310.19

+1.43%↑

NVO

56.31

-0.48%↓

LLY

743.42

+1.14%↑

JNJ

178.62

+0.73%↑

ABBV

212.4

+0.07%↑

UNH

310.19

+1.43%↑

NVO

56.31

-0.48%↓

Search

Royalty Pharma PLC (Class A)

Avatud

SektorTervishoid

36.55 0.49

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

36.3

Max

36.94

Põhinäitajad

By Trading Economics

Sissetulek

-403M

30M

Müük

10M

579M

P/E

Sektori keskmine

15.712

35.733

Aktsiakasum

1.06

Dividenditootlus

2.41

Kasumimarginaal

5.215

EBITDA

-375M

159M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+20.54% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.41%

3.13%

Järgmine dividendimakse kuupäev

10. sept 2025

Järgmine aktsia dividendi kuupäev (ex-date)

14. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-315M

21B

Eelmine avamishind

36.06

Eelmine sulgemishind

36.55

Uudiste sentiment

By Acuity

50%

50%

175 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Royalty Pharma PLC (Class A) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. juuni 2025, 10:49 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

Võrdlus sarnastega

Hinnamuutus

Royalty Pharma PLC (Class A) Prognoos

Hinnasiht

By TipRanks

20.54% tõus

12 kuu keskmine prognoos

Keskmine 43.6 USD  20.54%

Kõrge 55 USD

Madal 37 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Royalty Pharma PLC (Class A) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

4

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

33 / N/AToetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

175 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
help-icon Live chat